Bionovo, Inc. : to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society

Sept. 20, 2011 -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced that Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo, will present the results of a study on the effects of two botanically-derived, tissue selective estrogen receptor modulators for the treatment of obesity at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington DC on Friday, September 23, 2011.

 On average, women transitioning through menopause experience a 10-15 pound weight gain with a redistribution of fat to the abdomen. Menopausal changes of body weight and increased central distribution of body fat have been identified as independent predictors of cardiovascular disease and type 2 diabetes. Dr. Tagliaferri will present studies that identify a new class of botanically-derived, tissue selective estrogen receptor modulators in adipose tissue which cause weight loss in mice without the unwanted proliferative effects in breast and uterine tissue that are associated with cancer... Bionovo's Press Release -